Decitabine assists umbilical cord-derived mesenchymal stem cells in improving glucose homeostasis by modulating macrophage polarization in type 2 diabetic mice.
Jieqing GaoYu ChengHaojie HaoYaqi YinJing XueQi ZhangLin LiJiejie LiuZongyan XieSongyan YuBing LiWeidong HanYi-Ming MuPublished in: Stem cell research & therapy (2019)
Our data suggest that MSCs combined with decitabine can more effectively alleviate insulin resistance and prolong and enhance the anti-diabetic effect of MSCs in T2D mice in part by prompting M2 polarization in a PPARγ-dependent manner. Thus, decitabine may be an applicable addition to MSCs for diabetes therapy. UC-MSCs combined with decitabine activate the IL4R/STAT6/STAT3/PPARγ axis to further promote M2 macrophage polarization in adipose tissue, reduce inflammation, improve insulin sensitivity, and lead to better glucose metabolism and long-term hypoglycemic effects.
Keyphrases
- umbilical cord
- mesenchymal stem cells
- insulin resistance
- acute myeloid leukemia
- adipose tissue
- type diabetes
- high fat diet induced
- high fat diet
- metabolic syndrome
- cell proliferation
- skeletal muscle
- bone marrow
- polycystic ovary syndrome
- oxidative stress
- cell therapy
- glycemic control
- signaling pathway
- electronic health record
- blood glucose
- fatty acid
- big data
- blood pressure
- weight loss
- machine learning
- smoking cessation